ClinicalTrials.gg

Program

dipropizine

Also written as “R1_PBK_M2301 (levodropropizine)”, “Levopront® syrup 30 mg/5 ml” and “Levotuss”.

Its studies are mostly in Cough · Bronchitis, Chronic, led by 5 companies.

Furthest: phase 3, since Aug 6, 20105 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ache Laboratorios Farmaceuticos10 open or runningphase 3since Aug 6, 2010Aug 6, 2010none ahead
Dompé Farmaceutici S.p.A10 open or runningphase 3since Jan 28, 2019Jan 28, 2019none ahead
Hanmi Pharmaceutical10 open or runningphase 1since Apr 5, 2012Apr 5, 2012none ahead
Hyundai Pharm10 open or runningphase 3since Mar 30, 2018Mar 30, 2018none ahead
Pharmbio Korea11 open or runningphase 1since Aug 20, 2025Aug 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2010First study: phase 3 study in InflammationNew to Ache Laboratorios FarmaceuticosAche Laboratorios Farmaceuticos · NCT01177852
  2. Apr 5, 2012Hanmi Pharmaceutical's first study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01573663 · 21 enrolled · Korea, Republic of
  3. Mar 30, 2018Hyundai Pharm's first study: phase 3 study in Bronchitis, ChronicNew to Hyundai PharmHyundai Pharm · NCT03489837 · 272 enrolled · Korea, Republic of
  4. Jan 28, 2019Dompé Farmaceutici S.p.A's first study: phase 3 study in CoughNew to Dompé Farmaceutici S.p.ADompé Farmaceutici S.p.A · NCT03837938 · 184 enrolled · Russian Federation
  5. Aug 20, 2025Pharmbio Korea's first study: phase 1 study in Healthy VolunteersNew to Pharmbio KoreaPharmbio Korea · NCT07161180 · 32 planned · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07161180Healthy Volunteers · South Korea1RecruitingPharmbio KoreaOct 30, 202532
NCT03837938Cough · Russian Federation3CompletedDompé Farmaceutici S.p.AMar 6, 2018184
NCT03489837Bronchitis, Chronic · Korea, Republic of3CompletedHyundai PharmOct 2018272
NCT01573663Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalApr 201221
NCT01177852Inflammation3WithdrawnAche Laboratorios FarmaceuticosApr 20120

How it is read

Names in the registry

  • “R1_PBK_M2301 (levodropropizine)”, 1 entry
  • “Levopront® syrup 30 mg/5 ml”, 1 entry
  • “Levotuss”, 1 entry
  • “diphenhydramine + dropropizine + pseudoephedrine”, 1 entry
  • “Ambroxol and Levodropropizine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.